GERD Clinical Trials 2023

Browse 19 Gerd Medical Studies Across 61 Cities

2 Phase 3 Trial · 77 Gerd Clinics

Reviewed by Michael Gill, B. Sc.
10 Gerd Clinical Trials Near Me
Top Hospitals for Gerd Clinical Trials
Image of Vanderbilt University Medical Center in Tennessee.
Vanderbilt University Medical Center
Nashville
2Active Trials
6All Time Trials for Gerd
2005First Gerd Trial
Image of Mayo Clinic Florida in Florida.
Mayo Clinic Florida
Jacksonville
1Active Trials
2All Time Trials for Gerd
2012First Gerd Trial
Image of Medical College of Wisconsin in Wisconsin.
Medical College of Wisconsin
Milwaukee
1Active Trials
2All Time Trials for Gerd
2011First Gerd Trial
Image of Reza Shaker in Wisconsin.
Reza Shaker
Milwaukee
1Active Trials
1All Time Trials for Gerd
2014First Gerd Trial
Image of Kansas City VA Hospital in Missouri.
Kansas City VA Hospital
Kansas City
1Active Trials
1All Time Trials for Gerd
2022First Gerd Trial
Top Cities for Gerd Clinical Trials
Image of Nashville in Tennessee.
Nashville
4Active Trials
Vanderbilt University Medical CenterTop Active Site
Image of Atlanta in Georgia.
Atlanta
4Active Trials
Children's Center for Digestive Health Care, LLCTop Active Site
Gerd Clinical Trials by Phase of TrialGerd Clinical Trials by Age Group
< 18 Gerd Clinical Trials
4Active Gerd Clinical Trials
Most Recent Gerd Clinical TrialsTop Treatments for Gerd Clinical Trials
Treatment Name
Active Gerd Clinical Trials
All Time Trials for Gerd
First Recorded Gerd Trial
Breath Test Evaluation for SIBO
1
1
2023
Shaker Pressure Band GERD patients with external laryngeal pressure
1
1
2011
Patients with supra-esophageal gastroesophageal reflux disease
1
1
2014
Anti-reflux mucosal ablation (ARAT)
1
1
2022
Drug Product
1
1
2023
Recently Completed Studies with FDA Approved Treatments for Gerd
Treatment
Year
Sponsor
Vonoprazan
2022
Phathom Pharmaceuticals, Inc.
Vonoprazan
2022
Phathom Pharmaceuticals, Inc.
Vonoprazan
2021
Phathom Pharmaceuticals, Inc.
dexlansoprazole
2017
Northwestern University

What Are GERD Clinical Trials?

GERD is the abbreviation of Gastroesophageal Reflux Disease. The condition is characterized by the repeated flow of stomach acid back into the esophagus. The esophagus is the tube that connects the mouth and stomach. The acid reflux irritates the esophagus lining. Many individuals experience acid reflux. However, if acid reflux occurs repeatedly, it can lead to Gastroesophageal Reflux Disease. Common GERD symptoms include heartburn after eating, the backwash of food, chest pain, and dysphagia.

GERD clinical trials are conducted to review and learn new ways to diagnose, prevent, and treat the disease. Recent studies are focused on discovering Voice-enabled AI for GERD diagnosis and the impact of diaphragmatic breathing on gastroesophageal reflux.

Why Is GERD Being Studied Through Clinical Trials?

The occurrence of GERD is becoming common. According to a research finding, GERD prevalence was 22.8 percent. Moreover, nearly 26.2 percent of women were affected by it, higher than men (18.9 percent). GERD can occur at any age. Eighty-four percent more children between 2 and 17 were hospitalized in 2005 compared to 1998. The cost of hospitalization for GERD in 2005 was $622 million.

The Niddk statistics show that 4.7 million individuals were hospitalized, and approximately 1,653 deaths occurred because of GERD in 2010. The condition can develop due to obesity, smoking, and medication such as antidepressants and painkillers.

Due to high prevalence and hospitalization costs, GERD clinical trials are being carried out actively by researchers worldwide. Through these studies, researchers can determine how GERD impacts lives, how people react to different treatments, and how lifestyle changes can ease symptoms. Clinical trials are essential to control and minimize the prevalence of GERD in adults and children.

What Are the Types of Treatments Available for GERD?

Multiple treatments are available for managing Gastroesophageal Reflux Disease. These include non-prescription and prescription medications. For example, a clinical trial was performed to determine the efficacy of esomeprazole for GERD. Despite controversies, the trial results showed that 40 mg esomeprazole given to patients for eight weeks healed erosive GERD at a higher rate.

Surgical treatments for GERD such as:

  • Fundoplication
  • LINX device 
  • TIF (Transoral incisionless fundoplication) 

What Are Some Recent Breakthrough Clinical Trials for GERD?

2017: Addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy- This study concluded that by adding Gaviscon to PPI therapy, GERD symptoms were reduced. However, a similar response was also witnessed for the placebo. Hence, more research is underway.

2020: LINX® Reflux Management System to Bridge the “Treatment Gap”-This systematic review was carried out according to the PRISMA guidelines. Over 35 studies and clinical trials were observed to investigate the efficacy and safety of MSA (magnetic sphincter augmentation) using the LINX® device to resolve GERD symptoms. A total of 2511 patients were included. 

The findings suggest that MSA effectively minimizes typical GERD symptoms. It bridges the gap between Laparoscopic fundoplication (LF) and maxed-out treatments. LINX system treatment is intended for patients who are not suitable candidates for LF and have unsatisfactory results with other medical treatments.

Who Are Some of the Key Opinion Leaders / Researchers / Institutions Conducting GERD Clinical Trial Research?

The National Institute Of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts clinical trials to gain new knowledge on many health conditions and diseases, including gastric diseases.

Division of Gastroenterology DoM at Penn is a dedicated and robust unit with more than 70 faculty members. They have scientific and clinical expertise covering multiple areas of modern gastroenterology.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: August 15th, 2023

References1 Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. doi: 10.1016/s0016-5085(97)70025-8. https://pubmed.ncbi.nlm.nih.gov/91368212 Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. https://pubmed.ncbi.nlm.nih.gov/91368213 El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13. Review. https://pubmed.ncbi.nlm.nih.gov/238532134 El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13. https://pubmed.ncbi.nlm.nih.gov/238532135 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825-31. doi: 10.1056/NEJM199903183401101. https://pubmed.ncbi.nlm.nih.gov/100808446 Fayad L, Oberbach A, Schweitzer M, Askin F, Voltaggio L, Larman T, Enderle M, Hahn H, Khashab MA, Kalloo AN, Kumbhari V. Gastric mucosal devitalization (GMD): translation to a novel endoscopic metabolic therapy. Endosc Int Open. 2019 Dec;7(12):E1640-E1645. doi: 10.1055/a-0957-3067. Epub 2019 Nov 25. https://pubmed.ncbi.nlm.nih.gov/317885467 Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825-31. https://pubmed.ncbi.nlm.nih.gov/100808448 Manner H, Neugebauer A, Scharpf M, Braun K, May A, Ell C, Fend F, Enderle MD. The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study. United European Gastroenterol J. 2014 Oct;2(5):383-90. doi: 10.1177/2050640614544315. https://pubmed.ncbi.nlm.nih.gov/253603169 Inoue H, Ito H, Ikeda H, Sato C, Sato H, Phalanusitthepha C, Hayee B, Eleftheriadis N, Kudo SE. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. Ann Gastroenterol. 2014;27(4):346-351. https://pubmed.ncbi.nlm.nih.gov/2533078410 Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 2;143(3):199-211. https://pubmed.ncbi.nlm.nih.gov/16061918